How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,900 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia? Full Text available with Trip Pro

Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia? Men often experience deterioration of sexual function after the use of α-blockers and 5-α reductase inhibitors for the treatment of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia. Thus, an alternative treatment with water vapor thermal therapy (Rezūm System, Boston Scientific, Marlborough, MA, USA) which (...) with the Rezūm procedure. A limitation of the study is the use of 2 different, although validated sexual function inventories (Brief Male Sexual Function Inventory and International Index of Erectile Function).A single water vapor thermal therapy procedure for targeted prostate tissue ablation for LUTS/ benign prostatic hyperplasia had no deleterious effect on 4 sexual function domains compared with appreciable worsening of sexual function after long-term single or combination drug use. McVary KT, Rogers T

2018 Journal Of Sexual Medicine Controlled trial quality: uncertain

222. Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study. (Abstract)

Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study. To explore the role of cholecalciferol for the prophylaxis against recurrent urinary tract infection (UTI) in patients with benign prostatic hyperplasia (BPH).Our randomized, uncontrolled prospective study included 389 naïve BPH patients with moderate/severe symptoms, consecutively. The patients were randomly allocated to two groups (...) ; group-A included 193 patients who received tamsulosin, while group-B included another 196 patients who received tamsulosin with cholecalciferol. The study population was followed up for 2 years after the start of the treatment. For all the patients enrolled, clinical evaluation, imaging studies (abdominal and trans-rectal ultrasonography), and laboratory investigations [including urinalysis, urine culture with antibiotic susceptibility testing for positive cultures and estimation of prostate

2018 World journal of urology Controlled trial quality: uncertain

223. Extreme Price Variation for Generic Benign Prostatic Hyperplasia Medications. (Abstract)

Extreme Price Variation for Generic Benign Prostatic Hyperplasia Medications. To characterize geographic variability of generic benign prostatic hyperplasia (BPH) medications in order to improve drug price transparency and improve patient access to affordable medication sources. This is of interest because BPH is one of the most common chronic diseases in men and contributes to individual healthcare cost. Medical therapy is the main treatment modality for BPH, burdening patients with lifelong

2018 Urology

224. Catheter-associated bacterial flora in patients with benign prostatic hyperplasia: shift in antimicrobial susceptibility pattern. Full Text available with Trip Pro

Catheter-associated bacterial flora in patients with benign prostatic hyperplasia: shift in antimicrobial susceptibility pattern. Men with urinary retention secondary to benign prostatic hyperplasia (BPH) are prone to genitourinary infections. Physicians should be aware of the current antimicrobial susceptibility pattern in this population if empirical treatment is needed. The goal of this study was to evaluate variations in prevalence, composition and antimicrobial susceptibility of bacterial

2018 BMC Infectious Diseases

225. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin. (Abstract)

The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin. Correction of benign prostatic hyperplasia (BPH) with lower urinary tract (LUT) symptoms (LUTS) is treated with drugs of different pharmacological classes having side effects including suppression of sexual function.To assess the effect of simultaneous intake of dutasteride and solifenacin on the reversibility (...) and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin. J Sex Med 2018;15:1579-1590.Copyright © 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

2018 Journal Of Sexual Medicine Controlled trial quality: uncertain

226. Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): a post hoc analysis of a prospective randomized placebo-contr Full Text available with Trip Pro

Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): a post hoc analysis of a prospective randomized placebo-contr Five-α reductase inhibitor (5ARI) therapy has been associated with sexual dysfunction in some patients. This study assessed the impact of a fixed-dose combination of the 5ARI dutasteride 0.5 mg and the α1 -adrenoceptor antagonist tamsulosin (...) 0.4 mg (DUT-TAM FDC) on Men's Sexual Health Questionnaire (MSHQ) domain scores in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH).This was a post hoc analysis of a double-blind, randomised, placebo-controlled, parallel-group, multicentre study in sexually active patients, aged ≥50 years, with a confirmed clinical diagnosis of BPH. Sexual activity, sexual desire, and bother domain scores of the MSHQ were assessed at baseline and at Months 1, 3, 6, 9

2018 International journal of clinical practice Controlled trial quality: uncertain

227. Paljung-San, a Traditional Herbal Medicine, Attenuates Benign Prostatic Hyperplasia In Vitro and In Vivo. (Abstract)

Paljung-San, a Traditional Herbal Medicine, Attenuates Benign Prostatic Hyperplasia In Vitro and In Vivo. Paljung-san is a traditional herbal medicine used widely for the treatment of urogenital diseases in East Asia. However, scientific evidence of the efficacy of Paljung-san and its mechanisms of action against benign prostatic hyperplasia (BPH) is not clearly established.We investigated the inhibitory effect of Paljung-san water extract (PSWE) and its mechanisms against BPH in vitro (...) showed reduced prostate weights and dihydrotestosterone levels and led to a restoration of normal prostate morphology. PSWE also decreased TP-induced Ki-67 and cyclin D1 protein levels in the prostatic tissues. Decreased glutathione reductase activity and increased malondialdehyde levels in the BPH groups were reversed by PSWE administration.PSWE attenuates the progression of BPH through anti-proliferative, anti-inflammatory and anti-oxidant activities in vitro and in vivo. Therefore, these data

2018 Journal of Ethnopharmacology

228. Efficacy and safety of tamsulosin 0.4mg single pills for the treatment in Asian patients with symptomatic benign prostatic hyperplasia of lower urinary tract symptoms: a randomized, double-blind, phase 3 trial. (Abstract)

Efficacy and safety of tamsulosin 0.4mg single pills for the treatment in Asian patients with symptomatic benign prostatic hyperplasia of lower urinary tract symptoms: a randomized, double-blind, phase 3 trial. To verify the efficacy and safety of tamsulosin 0.4 mg and tamsulosin 0.2 mg compared with those of placebo in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).A total of 494 patients from multiple centers participated in this double (...) -blind, randomized, phase 3 trial. Eligible patients were randomly assigned to the tamsulosin 0.4 mg group, tamsulosin 0.2 mg group or placebo group. The International Prostate Symptom Score (IPSS), maximum flow rate (Qmax), post-void residual (PVR) urine volume, blood pressure, heart rate and adverse events were compared among the three groups at 4, 8 and 12 weeks.A total of 494 BPH patients were analyzed. There were no differences in the baseline characteristics among the three groups. After 12

2018 Current medical research and opinion Controlled trial quality: predicted high

229. Effects of Qianlie Tongqiao Capsule on Bladder Weight and Growth Factors in Bladder Tissue of Rats with Testosterone-Induced Benign Prostatic Hyperplasia. Full Text available with Trip Pro

Effects of Qianlie Tongqiao Capsule on Bladder Weight and Growth Factors in Bladder Tissue of Rats with Testosterone-Induced Benign Prostatic Hyperplasia. Qianlie Tongqiao Capsule (QTC) is clinically confirmed to be efficacious and safe in treating lower urinary tract syndromes and bladder dysfunction that are induced by benign prostatic hyperplasia (BPH). However, the functional mechanisms of QTC remain unclear. We aim to investigate the effects of QTC on both bladder weight and several growth (...) in the bladder after prostatic obstruction, respectively. Furthermore, QTC balanced the Bcl-2/Bax ratio. Overall, these results reveal possible functional mechanisms of QTC in treating BPH-caused bladder dysfunction, and further studies are needed.

2018 Evidence-based Complementary and Alternative Medicine (eCAM)

230. Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats Full Text available with Trip Pro

Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats The present study investigated the role of androgen in the process of androgen-induced prostate hyperplasia in castrated rats and assessed the role of the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway in this process. Furthermore, the extent to which autophagy may affect the level of androgen-induced benign prostatic hyperplasia was also explored. A total (...) of 40 Sprague Dawley rats were randomly divided into four groups: Testosterone group, rapamycin group, 3-methyladenine (3-MA) group, and control group. The extent of hyperplasia in prostate tissue the apoptosis and autophagy were assayed. The prostate wet weight, volume and index in the testosterone group were significantly higher compared with the control group (P<0.05) and these factors were significantly lower in the rapamycin group compared with the testosterone group (P<0.05). HE staining

2018 Experimental and therapeutic medicine

231. An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with tre Full Text available with Trip Pro

An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with tre The aim of this study was to investigate the efficacy and tolerability of switching from 0.2 mg tamsulosin to 0.4 mg tamsulosin oral controlled absorption system (OCAS) over a 12-week period in Taiwanese men with lower urinary tract symptoms (...) (LUTS) associated with benign prostatic hyperplasia (BPH).Taiwanese male patients who were dissatisfied with treatment with 0.2 mg tamsulosin were enrolled in this clinical study and switched to 0.4 mg tamsulosin OCAS. Efficacy was assessed over a 12-week period by an International Prostate Symptom Score (IPSS) questionnaire and analysis of urinary flow by uroflowmetry.A statistically significant improvement was observed in total IPSS scores from baseline (14.94±7.41, moderate) to 12 weeks (7.36

2018 Clinical interventions in aging Controlled trial quality: uncertain

232. BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib Full Text available with Trip Pro

BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib The mechanisms involved in the development of benign prostatic hyperplasia (BPH) are poorly understood. One potential mechanism involved in BPH pathogenesis may involve altered expression of genes related to apoptosis and proliferation because reduced cell death and increased proliferation are thought to contribute to prostatic enlargement. This study examined (...) -2 and BCL-XL in BPH specimens from prostate cancer patients with BPH. These patients had no prior use of chronic NSAIDs and/or 5a-reductase inhibitors and were treated with celecoxib, finasteride, celecoxib plus finasteride or no treatment for 28 consecutive days prior to surgery. In all specimens, BCL-2 and BCL-XL staining was evident in both luminal and basal epithelial cells, with more intense staining in basal cells. Both luminal and basal cells exhibited decreased BCL-2 and BCL-XL staining

2018 American journal of clinical and experimental urology

233. Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA Full Text available with Trip Pro

Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are common conditions affecting the majority of elderly males. Here we report the results of a genome-wide association study of symptomatic BPH/LUTS in 20,621 patients and 280,541 controls of European ancestry, from Iceland and the UK. We discovered 23 genome-wide significant variants, located at 14 (...) loci. There is little or no overlap between the BPH/LUTS variants and published prostate cancer risk variants. However, 15 of the variants reported here also associate with serum levels of prostate specific antigen (PSA) (at a Bonferroni corrected P < 0.0022). Furthermore, there is a strong genetic correlation, rg = 0.77 (P = 2.6 × 10-11), between PSA and BPH/LUTS, and one standard deviation increase in a polygenic risk score (PRS) for BPH/LUTS increases PSA levels by 12.9% (P = 1.6×10-55

2018 Nature communications

234. Large bowel obstruction caused by urinary retention from benign prostate hyperplasia Full Text available with Trip Pro

Large bowel obstruction caused by urinary retention from benign prostate hyperplasia Although large bowel obstruction is a common surgical emergency, its occurrence due to bladder distension is rarely reported in the literature. We report a case of large bowel obstruction caused by bladder distention secondary to benign prostate hyperplasia in a 67-year-old man. This case demonstrates a grossly distended urinary bladder compressing the rectosigmoid colon against the sacrum, presenting

2018 Radiology Case Reports

235. Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model Full Text available with Trip Pro

Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model We investigated the benefits of the BKCa agonist 4-chloro-7-trifluoromethyl-10H-benzo[4,5]furo[3,2-b]indole-1-carboxylic acid (LDD175) combined with tamsulosin and finasteride, in a benign prostatic hyperplasia (BPH) rat model.Castration was performed by bilateral orchiectomy under ketamine anesthesia. A rat model of BPH was established by daily intramuscular administration of testosterone (...) -adrenoceptor mRNA and protein expression levels after treatment.Combined LDD175, tamsulosin, and finasteride significantly decreased prostatic index, serum hormone levels, epithelial thickness, and prostate expression of α1-adrenoceptors in BPH model rats. The 3-drug combination was more effective than any other combination or LDD175 alone.These results suggest that LDD175 addition to tamsulosin and finasteride may be beneficial for the treatment of BPH patients who do not respond to tamsulosin plus

2018 Drug design, development and therapy

236. Pharmacotherapy versus surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis. Full Text available with Trip Pro

Pharmacotherapy versus surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis. To evaluate the cost-effectiveness of using a surgery, such as transurethral resection of the prostate (TURP) or photoselective vaporisation of the prostate using greenlight laser (GL-PVP), as initial treatment for men with moderate-to-severe benign prostate hyperplasia (BPH) compared to the standard practice of using pharmacotherapy as initial

2018 BJU international

237. Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease: A Matched Cohort Study. (Abstract)

Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease: A Matched Cohort Study. Antipsychotics (APs) are known to exacerbate symptoms of benign prostate hyperplasia (BPH) and may even cause urinary retention. The anticholinergic effects of APs and their dopamine D2- and α-receptor blockade may lead to voiding dysfunction of BPH patients. The objective of our study was to investigate whether the use of APs is associated

2018 Journal of Clinical Psychopharmacology

238. The use of 5-alpha reductase inhibitors to manage benign prostatic hyperplasia and the risk of all-cause mortality. (Abstract)

The use of 5-alpha reductase inhibitors to manage benign prostatic hyperplasia and the risk of all-cause mortality. To compare the risk of mortality among men treated for benign prostatic hyperplasia (BPH) with 5 alpha-reductase inhibitors (5ARI) to those treated with alpha-blockers (AB) in community practice settings.We employed a retrospective matched cohort study in 4 regions of an integrated healthcare system. Men aged 50 years and older who initiated pharmaceutical treatment for BPH

2018 Urology

239. Re: Effect of Weight Reduction on the Severity of Lower Urinary Tract Symptoms in Obese Male Patients with Benign Prostatic Hyperplasia: A Randomized Controlled Trial. (Abstract)

Re: Effect of Weight Reduction on the Severity of Lower Urinary Tract Symptoms in Obese Male Patients with Benign Prostatic Hyperplasia: A Randomized Controlled Trial. 27479405 2018 07 30 2018 12 02 1527-3792 196 2 2016 08 The Journal of urology J. Urol. Re: Effect of Weight Reduction on the Severity of Lower Urinary Tract Symptoms in Obese Male Patients with Benign Prostatic Hyperplasia: A Randomized Controlled Trial. 501-3 10.1016/j.juro.2016.05.019 S0022-5347(16)30375-5 Kaplan Steven A SA (...) eng Journal Article Comment 2016 05 11 United States J Urol 0376374 0022-5347 AIM IM Korean J Urol. 2015 Mar;56(3):240-6; discussion 246-7 25763129 Humans Lower Urinary Tract Symptoms Male Obesity Prostatic Hyperplasia Weight Loss 2016 05 04 2016 8 2 6 0 2016 8 2 6 0 2018 7 31 6 0 ppublish 27479405 S0022-5347(16)30375-5 10.1016/j.juro.2016.05.019

2018 The Journal of urology Controlled trial quality: uncertain

240. Re: Comparison of Tamsulosin plus Serenoa repens with Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Korean Men: 1-Year Randomized Open Label Study. (Abstract)

Re: Comparison of Tamsulosin plus Serenoa repens with Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Korean Men: 1-Year Randomized Open Label Study. 27479407 2018 07 30 2018 12 02 1527-3792 196 2 2016 08 The Journal of urology J. Urol. Re: Comparison of Tamsulosin plus Serenoa repens with Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Korean Men: 1-Year Randomized Open Label Study. 503 10.1016/j.juro.2016.05.021 S0022-5347(16)30377-9 Kaplan Steven A SA eng (...) Journal Article Comment 2016 05 11 United States J Urol 0376374 0022-5347 0 Plant Extracts 0 Sulfonamides G3P28OML5I Tamsulosin AIM IM Urol Int. 2015;94(2):187-93 25614155 Humans Male Phytotherapy Plant Extracts Prostatic Hyperplasia Serenoa Sulfonamides Tamsulosin 2016 8 2 6 0 2016 8 2 6 0 2018 7 31 6 0 ppublish 27479407 S0022-5347(16)30377-9 10.1016/j.juro.2016.05.021

2018 The Journal of urology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>